OSLO, Norway--(BUSINESS WIRE)-- Regulatory News: DiaGenic ASA (“DiaGenic”) announces that Paul de Potocki will assume the position of President and CEO of DiaGenic. Paul de Potocki will succeed Henrik Lund, who has led the development of DiaGenic on an interim basis since April 2012. Paul de Potocki will assume the position as CEO medio September this year.
Paul de Potocki brings more than 20 years of international business management experience to the company. He joins DiaGenic after serving as CEO of Aerocrine AB, a medical device and diagnostic company pioneering a novel technology for the improved diagnosis and management of asthma. Prior to joining Aerocrine, he has served as Senior Vice President, Commercial and Strategic Development at Biovitrum AB. Paul has also served as Executive Vice President, Strategic Marketing at the German company Fresenius Kabi, as well as Divisional Vice President, Global Sales and Strategic Marketing with Pharmacia. Prior to this, he held various international commercial management positions within the Unilever group.
“DiaGenic is entering a new stage of development with accelerating acceptance of the important role DiaGenic’s blood based diagnostics may play in the management of neurodegenerative disorders," says Ingrid Wiik, interim chairman of the board. "Paul's significant industry experience makes him exceptionally qualified to meet the challenges of achieving our goal of bringing DiaGenic’s products to the benefit of patients in international markets."
DiaGenic’s nomination committee proposes for the company’s annual general meeting on June 26th that Henrik Lund, interim CEO, shall resume his former position as chairman of the company on the effective date of Paul de Potocki’s appointment as CEO. An extraordinary general meeting will be called to approve a new option program in connection with the appointment of the new CEO.
About DiaGenic ASA
DiaGenic seeks to create value for patients, partners, and investors by developing innovative and more patient friendly methods for early detection of diseases utilizing DiaGenic’s unique concept. The concept implies that a disease evokes systemic responses in the blood unique for the disease, and which can be measured by using blood samples.
DiaGenic is a world leader in identifying these gene expression signatures in peripheral blood and is focused on the development of biomarkers in the field of Alzheimer’s disease and Parkinson’s disease. DiaGenic’s Alzheimer’s disease development program includes the CE marked diagnostic test ADtect®, for detection of mild to moderate Alzheimer’s disease, and MCItect®which is under development for identifying patients with very early stages of Alzheimer’s disease (prodromal AD).
DiaGenic’s concept is protected through an extensive patent portfolio. DiaGenic promotes its products and services towards leading pharmaceutical, imaging and diagnostic companies. DiaGenic is located in Norway and listed on the Oslo Stock Exchange. For more information please visit: www.diagenic.com
This information was brought to you by Cision http://www.cisionwire.com
Contact and enquiries:
Ingrid Wiik, Interim Chairman of the Board
phone: +47 90051433
Henrik Lund, Interim CEO, phone: +47 90971219